Edition:
India

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

54.26USD
1:30am IST
Change (% chg)

$0.39 (+0.72%)
Prev Close
$53.87
Open
$53.68
Day's High
$55.34
Day's Low
$53.68
Volume
211,842
Avg. Vol
219,230
52-wk High
$71.99
52-wk Low
$41.68

Chart for

About

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $2,305.92
Shares Outstanding(Mil.): 42.46
Dividend: --
Yield (%): --

Financials

BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets

* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR & OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS

17 Apr 2018

FDA approves Ultragenyx's drug for rare form of rickets

The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical Inc's treatment for a rare and inherited form of rickets, a condition that causes weak bones, the agency said on Tuesday.

17 Apr 2018

FDA approves Ultragenyx's treatment for rare type of rickets

April 17 The U.S. Food and Drug Administration approved on Tuesday Ultragenyx Pharmaceutical Inc's treatment, Crysvita, for x-linked hypophosphatemia, a rare type of rickets.

17 Apr 2018

BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301

* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

07 Mar 2018

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

23 Feb 2018

BRIEF-Ultragenyx Reports Q4 Loss Per Share $1.89

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

21 Feb 2018

BRIEF-Ultragenyx Prices Public Offering Of 4.39 Mln Common Shares At $57/Share

* ULTRAGENYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Ultragenyx Announces Proposed Public Offering Of Common Stock

* ULTRAGENYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

BRIEF-Capital International Investors Reports 10.3 Pct Passive Stake In Ultragenyx

* CAPITAL INTERNATIONAL INVESTORS REPORTS 10.3 PERCENT PASSIVE STAKE IN ULTRAGENYX PHARMACEUTICAL INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text for Eikon: (http://bit.ly/2D1HymY) Further company coverage:

11 Jan 2018

BRIEF-Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

* ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS

04 Jan 2018

Earnings vs. Estimates